Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized open-label study of QHRD211 injection in children with growth disorder due to endogenous growth hormone deficiency
CTR20243034Phase 2Active
- Sponsor
- Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of QHRD211 in growth hormone deficiency (GHD), sponsored by Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute. Started Nov 2024; status: active.
02
Drugs
QHRD211
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20243034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243034.